METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further lines therapy options include anti-EGFR therapy, eligible for patients with wild-type KRAS (cetuximab and panitumumab), and relatively new drug — regorafenib, which could be used for all patients.The aim...
| المؤلفون الرئيسيون: | , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | Russian |
| منشور في: |
IRBIS LLC
2016-09-01
|
| سلاسل: | Фармакоэкономика |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.pharmacoeconomics.ru/jour/article/view/146 |